• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

    57.90 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 235
    Open 57.90
    Bid (Size) 56.22 (100)
    Ask (Size) 57.79 (100)
    Prev. Close 57.90
    Today's Range 57.90 - 57.90
    52wk Range 26.74 - 63.95
    Shares Outstanding 63,562,303
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
    Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon... 
    Via Finterra
    Topics ETFs Intellectual Property

    Performance

    YTD
    +30.1%
    +30.1%
    1 Month
    +35.8%
    +35.8%
    3 Month
    +32.6%
    +32.6%
    6 Month
    +55.6%
    +55.6%
    1 Year
    +63.2%
    +63.2%

    More News

    Read More
    News headline image
    Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner ↗
    Via Chartmill
    News headline image
    The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
    Via Stocktwits
    News headline image
    Xenon Pharmaceuticals Announces Proposed Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Top stock movements in today's session. ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
    Via MarketMinute
    Topics Artificial Intelligence Economy

    Frequently Asked Questions

    Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?
    Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.
    What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?
    Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?
    The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market
    What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?
    The current price of Xenon Pharmaceuticals Inc. - Common Shares is 57.90
    When was Xenon Pharmaceuticals Inc. - Common Shares last traded?
    The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 03/12/26 04:00 PM ET
    What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?
    The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 3.68B
    How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?
    Xenon Pharmaceuticals Inc. - Common Shares has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.